VIVUS, Inc. (Nasdaq: VVUS) announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE